Morphic Holding inc (NASDAQ: MORF) |
|
Price: $56.9900
$0.02
0.035%
|
Day's High:
| $57
| Week Perf:
| 0.16 %
|
Day's Low: |
$ 56.97 |
30 Day Perf: |
1.28 % |
Volume (M): |
1,796 |
52 Wk High: |
$ 57.00 |
Volume (M$): |
$ 102,343 |
52 Wk Avg: |
$37.42 |
Open: |
$56.98 |
52 Wk Low: |
$25.25 |
|
|
Market Capitalization (Millions $) |
2,855 |
Shares
Outstanding (Millions) |
50 |
Employees |
44 |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-180 |
Cash Flow (TTM) (Millions $) |
-166 |
Capital Exp. (TTM) (Millions $) |
1 |
Morphic Holding Inc
Morphic Holding Inc. is a technology company that focuses on developing and commercializing shape-shifting user interfaces for electronic devices. The company aims to create adaptive and personalized interfaces that can transform to meet the specific needs and preferences of individual users.
These shape-shifting interfaces, termed morphic interfaces, have the ability to dynamically adjust their appearance, layout, and functionality based on user input or contextual cues. The goal is to provide a more intuitive and efficient user experience across various devices, such as smartphones, tablets, computers, and wearable technology.
Morphic Holding Inc. invests heavily in research and development to continuously improve and expand the capabilities of its morphic interfaces. The company strives to make technology more accessible and inclusive, catering to different age groups, skill levels, and physical abilities.
Overall, Morphic Holding Inc. aims to revolutionize the way people interact with electronic devices by replacing static and rigid interfaces with adaptable and personalized interfaces that enhance user productivity, comfort, and satisfaction.
Company Address: 35 Gatehouse Drive Waltham 2451 MA
Company Phone Number: 996-0955 Stock Exchange / Ticker: NASDAQ MORF
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Morphic Holding Inc
Morphic Therapeutic's Journey in the Pharmaceutical Sector: A Focus on Innovation and Market Challenges WALTHAM, Mass., May 31, 2024 ? Morphic Therapeutic (Nasdaq: MORF), a promising biotechnology company making strides in oral integrin therapies for the treatment of serious chronic diseases, is preparing to showcase its progress at the upcoming 2024 Jefferies Global Healthcare Conference. Scheduled for June 5 at 10:30 AM ET, the fireside chat will feature members of Morphic?s management team, providing an opportunity to share insights on the company's development strategies and the future of its innovative therapies. Recent conversations surrounding Morphic Therapeutic highlight both the company's ambition and the challenges it faces in a competitive pharmaceutical landscape. Despite ambitious plans, Morphic?s stock performance has faced hurdles expressed by various recent financial analyses. Notably, its shares have trailed the S&P 500 and Nasdaq 100, which have recently reached record highs. For context, the overall market has returned 16.07% year-to-date, while MORF shares have struggled to find similar momentum.
|
Stocks on the Move
Published Tue, Jul 16 2024 8:48 AM UTC
Behind the ...
|
Morphic Holding Inc
Morphic Holding Inc, a pharmaceutical company focused on developing oral integrin therapies, recently released its financial results for the January to March 31, 2024 interval. While the company reported an increased deficit per share compared to the previous year, there are several positive developments to note. For the first quarter of 2024, Morphic Holding Inc's deficit per share rose to $-0.91, up from $-0.90 in the same period a year ago and $-0.84 in the previous reporting period. The company also reported unchanged revenue of $0.00 million, down from $0.52 million in the same reporting period last year. Despite these financial challenges, Morphic Holding Inc ended the quarter with $659 million in cash, ensuring stability for the near future.
|
Morphic Holding Inc
Morphic Holding Inc, a major pharmaceutical preparations company, recently reported its financial performance for the time-frame ending December 31, 2023. The company experienced a significant increase in its shortfall per share compared to the previous year, with a per share shortfall of $-0.84 as opposed to $-0.62. Additionally, there was a surge in the shortfall from the previous quarter, with the company reporting a per share shortfall of $-0.73. Despite these concerning figures, the company's revenue remained unchanged at $0.00 million, down from $6.14 million in the same quarter a year prior. Morphic Holding Inc realized a net shortfall of $-40.735 million for the financial period ending in 2023, a marked increase from $-24.377 million the previous year.
|
Morphic Holding Inc
Morphic Holding Inc, a biopharmaceutical company specializing in the development of oral integrin therapies for the treatment of autoimmune and inflammatory diseases, presented positive data for its drug MORF-057 at UEG Week 2023. The Phase 2a data showed promising results in patients with moderate to severe ulcerative colitis, offering hope for improved treatment options in this challenging condition. In addition to this positive development, Morphic Holding Inc also released its financial results for the third quarter of 2023. The company reported a decrease in its loss per share from $-0.78 to $-0.73 compared to the previous year. Furthermore, the EPS improved from $-0.92 to $-0.73 per share from the previous reporting period. Although the revenue remained unchanged at $0.00 million, this stability is still significant considering the challenges faced by many companies in the current economic climate.
|
Per Share |
Current |
Earnings (TTM) |
-3.63 $ |
Revenues (TTM) |
-
|
Cash Flow (TTM) |
- |
Cash |
12.54 $
|
Book Value |
12.35 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-3.63 $
|
Revenues (TTM) |
- |
Cash Flow (TTM) |
- |
Cash |
12.54 $
|
Book Value |
12.35 $ |
Dividend (TTM) |
0 $ |
|
|
|
|